文献速递围术期管理与 ERAS

右美托咪定对心脏手术后围术期神经认知结局的影响:随机对照试验的系统综述与Meta分析

The Effects of Dexmedetomidine on Perioperative Neurocognitive Outcomes After Cardiac Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
PubMed 文献 · Ann Surg · 2021-08-27

该系统综述与Meta分析纳入9项随机对照试验共942例心脏手术成人患者,比较围术期右美托咪定与安慰剂或无右美托咪定的认知功能影响≥术后1周。结果显示右美托咪定降低延迟性神经认知功能障碍(dNCR)发生率(OR 0.39,95%CI 0.25-0.61,P<0.0001),但谵妄发生率和血流动力学不稳定发生率无显著差异。

要点

  • 右美托咪定降低心脏手术后1周dNCR发生率(OR 0.39,95%CI 0.25-0.61)。
  • 右美托咪定不降低术后谵妄发生率(OR 0.69,95%CI 0.35-1.34,P=0.27)。
  • 右美托咪定不增加血流动力学不稳定发生率(OR 1.14,95%CI 0.59-2.18,P=0.70)。

核心结论

  • 围术期右美托咪定可降低心脏手术后1周延迟性神经认知功能障碍的发生率。
  • 右美托咪定对术后谵妄和血流动力学不稳定发生率无显著影响。
  • 未来需用稳健认知评估和客观诊断标准研究长期认知结局。

研究设计与样本

  • 系统综述与Meta分析,纳入成人心脏手术随机对照试验,比较围术期右美托咪定与安慰剂或替代镇静。
  • 定性分析纳入9项试验共942例参与者,其中7项纳入dNCR的Meta分析。
  • 认知功能评估时间≥术后1周,数据由三名评价者独立平行提取,采用随机效应模型合并。

主要发现

  • 右美托咪定组dNCR发生率低于安慰剂/无右美托咪定组(OR 0.39,95%CI 0.25-0.61,P<0.0001)。
  • 谵妄发生率两组无差异(OR 0.69,95%CI 0.35-1.34,P=0.27)。
  • 血流动力学不稳定发生率两组无差异(OR 1.14,95%CI 0.59-2.18,P=0.70)。

关键数值与推荐

  • dNCR定义为认知功能下降至少达到最小临床重要差异或可靠变化指数≥1.96等公认替代指标。
  • 纳入标准为成人心脏手术、围术期右美托咪定对比安慰剂或替代镇静、评估术后≥1周认知功能。
  • 偏倚评估采用Cochrane协作工具。

临床怎么用

  • 心脏手术围术期可考虑使用右美托咪定以降低短期延迟性神经认知功能障碍风险。
  • 右美托咪定不增加血流动力学不稳定风险,但需注意谵妄发生率未显著改善。

局限性

  • 纳入试验认知评估工具、评估时机和功能障碍定义不一致。
  • 仅7项试验纳入dNCR的Meta分析,样本量有限。
  • 缺乏长期认知结局数据及采用新围术期神经认知障碍命名和客观诊断标准的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this systematic review and meta-analysis is to examine the effect of DEX on delayed dNCR (cognitive dysfunction ≥ 1 week postoperative) after cardiac surgery. BACKGROUND: DEX has salutary effects on cognitive outcomes following cardiac surgery, however, studies are limited by inconsistent assessment tools, timing, and definitions of dysfunction. It is imperative to identify accurate point estimates of effect of DEX on clinically relevant changes in cognitive function. METHODS: Randomized trials of adults undergoing cardiac surgery comparing perioperative DEX to placebo or alternate sedation and assessing cognitive function ≥ 1 week postoperative were included. Data was abstracted by three reviewers independently and in parallel according to PRISMA guidelines. The primary outcome is dNCR. To classify as dNCR, cognitive function must decrease by at least the minimal clinically important difference or accepted alternate measure (eg, Reliable Change Index ≥1.96). Bias was assessed with the Cochrane Collaboration tool. Data was pooled using a random effects model. RESULTS: Nine trials (942 participants) were included in qualitative analysis, of which seven were included in the meta-analysis of dNCR. DEX reduced the incidence of dNCR (OR 0.39, 95% CI 0.25-0.61, P < 0.0001) compared to placebo/no DEX. There was no difference in the incidence of delirium (OR 0.69, 95% CI 0.35-1.34, P = 0.27) or incidence of hemodynamic instability (OR 1.14, 95% CI 0.59-2.18, P = 0.70) associated with perioperative DEX. CONCLUSIONS: DEX reduced the incidence of dNCR 1 week after cardiac surgery. Although this meta-analysis demonstrates short term cognitive outcomes are improved after cardiac surgery with perioperative DEX, future trials examining long term cognitive outcomes, using robust cognitive assessments, and new perioperative neurocognitive disorders nomenclature with objective diagnostic criteria are necessary.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Singh A, Brenna CTA, Broad J, et al. The Effects of Dexmedetomidine on Perioperative Neurocognitive Outcomes After Cardiac Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Ann Surg. 2021. PMID: 35543164. doi:10.1097/SLA.0000000000005196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。